Who is sponsoring NCT04320732?

NCT04320732 is sponsored by Oslo University Hospital.

What drugs are being tested in NCT04320732?

Interventions in NCT04320732: Observation of behavior and COVID-19 infection will be conducted..

What condition does NCT04320732 study?

NCT04320732 studies Coronavirus.

Is NCT04320732 still recruiting?

NCT04320732 is currently recruiting now. Last updated 13 December 2021.

Last reviewed 2021-12-13 · How we verify

NCT04320732

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Risk Factors for Community- and Workplace Transmission of COVID-19

Recruiting now Last updated 13 December 2021

What this trial tests

trial testing Observation of behavior and COVID-19 infection will be conducted. in Coronavirus in 250,000 participants. Currently enrolling.

Timeline

27 March 2020

Primary endpoint
27 March 2025

20 March 2030

Quick facts

Lead sponsor	Oslo University Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	250,000
Start date	27 March 2020
Primary completion	27 March 2025
Estimated completion	20 March 2030
Sites	1 location across Norway

Drugs / interventions tested

Observation of behavior and COVID-19 infection will be conducted.

Conditions studied

Coronavirus — all drugs for Coronavirus →

Sponsor

Oslo University Hospital

Who can join

18 and older, any sex, with Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project is an epidemiological observational study based on an electronic questionnaire on risk factors for COVID-19 in the community and healthcare setting.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Potential Antiviral Options against SARS-CoV-2 Infection.
Ianevski A, Yao R, Fenstad MH, Biza S, et al · · 2020 · cited 73× · PMID 32545799 · DOI 10.3390/v12060642
EWAS of post-COVID-19 patients shows methylation differences in the immune-response associated gene, IFI44L, three months after COVID-19 infection.
Lee Y, Riskedal E, Kalleberg KT, Istre M, et al · · 2022 · cited 24× · PMID 35798818 · DOI 10.1038/s41598-022-15467-1
Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection.
Brunvoll SH, Nygaard AB, Fagerland MW, Holland P, et al · · 2023 · cited 17× · PMID 36375693 · DOI 10.1016/j.ijid.2022.11.009
Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity.
Søraas A, Grødeland G, Granerud BK, Ueland T, et al · · 2022 · cited 13× · PMID 36159859 · DOI 10.3389/fimmu.2022.964525
Potential antiviral options against SARS-CoV-2 infection
Ianevski A, Yao R, Fenstad MH, Biza S, et al · · 2020 · cited 8× · DOI 10.1101/2020.05.12.091165
Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.
Alirezaylavasani A, Skeie LG, Egner IM, Chopra A, et al · · 2024 · cited 6× · PMID 39384763 · DOI 10.1038/s41541-024-00972-3
Dispersion of SARS-CoV-2 in air surrounding COVID-19-infected individuals with mild symptoms.
Gohli J, Anderson AM, Brantsaeter AB, Bøifot KO, et al · · 2022 · cited 3× · PMID 35225394 · DOI 10.1111/ina.13001
Temporal trajectories of long-COVID symptoms in adults with 22 months follow-up in a prospective cohort study in Norway.
Ellingjord-Dale M, Nygaard AB, Støer NC, Bø R, et al · · 2024 · cited 2× · PMID 39419167 · DOI 10.1016/j.ijid.2024.107263

Verify or expand the search:

Other recruiting trials for Coronavirus

Currently open trials in the same condition.

NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting

Other Oslo University Hospital trials

Trials by the same sponsor.

NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04320732 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
Last refreshed: 13 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04320732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing